Claims
- 1. A compound of the formula R1 is hydrogen, (C1-C6)alkyl, unconjugate (C3-C6)alkenyl, XC(═O)R13, benzyl or —CH2CH2—O—(C1-C4)alkyl; R2 and R3, together with the carbons to which they are attached, form a four to seven membered monocyclic, or ten to fourteen membered bicyclic, carbocyclic ring that can be saturated or unsaturated, wherein from one to three of the nonfused carbon atoms of said monocyclic rings, and from one to five of the carbon atoms of said bicyclic rings that are not part of the benzo rings shown in formula I, may optionally and independently be replaced by a nitrogen, oxygen or sulfur, and wherein said monocyclic and bicyclic rings may optionally be substituted with one or more substituents that are selected, independently, from (C1-C6) alkyl optionally substituted with from one to seven fluorine atoms; (C1-C6)alkoxy optionally substituted with from one to seven fluorine atoms; nitro, cyano, halo, (C2-C6)alkenyl, (C2-C6)alkynyl, hydroxy, amino, (C1-C6)alkylamino and ((C1-C6)alkyl)2amino, —CO2R4, —CONR5R6, —SO2NR7R8, —C(═O)R13 and —XC(═O)R13; wherein each R4, R5, R6, R7, R8 and R13 is selected, independently, from hydrogen and (C1-C6) alkyl, or R5 and R6, or R7 and R8 together with the nitrogen to which they are attached, form a pyrrolidine, piperidine, morpholine, azetidine, piperazine, —N—(C1-C6)alkylpiperazine or thiomorpholine ring, or a thiomorpholine ring wherein the ring sulfur is replaced with a sulfoxide or sulfone; and each X is, independently, (C1-C6)alkylene; or a pharmaceutically acceptable salt thereof.
- 2. A compound according to claim 1, wherein R2 and R3, together with the benzo of formula I, form a bicyclic ring system selected from the following: wherein R10 and R17 are selected, independently, from (C1-C6) alkyl optionally substituted with from one to seven fluorine atoms; (C1-C6) alkoxy optionally substituted with from one to seven fluorine atoms; (C2-C6)alkenyl, (C2-C6)alkynyl, hydroxy, amino, (C1-C6)alkylamino and ((C1-C6)alkyl)2amino, —CO2R4, —CONR5R6, —SO2NR7R8, —C(═O)R13 and —XC(═O)R13 and wherein R4, R5, R6, R7, R8 and R13 are as defined in claim 1.
- 3. A compound according to claim 1 selected from the group consisting of:5,7,13-triazatetracyclo[9.3.1.02,10.04,8]pentadeca-2(10),3,5,8-tetraene; 7-methyl-5,7,13-triazatetracyclo[9.3.1.02,10.04,8]pentadeca-2(10),3,5,8-tetraene; 6-methyl-5,7,13-triazatetracyclo[9.3.1.02,10.04,8]pentadeca-2(10),3,5,8-tetraene; 7-propyl-5,7,13-triazatetracyclo[9.3.1.02,10.04,8]pentadeca-2(10),3,5,8-tetraene; 7-butyl-5,7,13-triazatetracyclo[9.3.1.02,10.04,8]pentadeca-2(10),3,5,8-tetraene; 6-methyl-7-isobutyl-5,7,13-triazatetracyclo[9.3.1.02,10.04,8]pentadeca-2(10),3,5,8-tetraene; 7-neopentyl-5,7,13-triazatetracyclo[9.3.1.02,10.04,8]pentadeca-2(10),3,5,8-tetraene; 6-methyl-7-neopentyl-5,7,13-triazatetracyclo[9.3.1.02,10.04,8]pentadeca-2(10),3,5,8-tetraene; 6-methyl-5-oxa-7,13-diazatetracyclo[9.3.1.02,10.04,8]pentadeca-2(10),3,6,8-tetraene; and pharmaceutically acceptable salts thereof.
- 4. A compound according to claim 1 which is:6-methyl-5-thia-7,13-diazatetracyclo[9.3.1.02,10.04,8]pentadeca-2(10),3,6,8-tetraene; or a pharmaceutically acceptable salt thereof.
- 5. A compound according to claim 1 which is:6-methyl-7-propyl-5,7,13-triazatetracyclo[9.3.1.02,10.04,8]pentadeca-2(10),3,5,8-tetraene; or a pharmaceutically acceptable salt thereof.
- 6. A compound according to claim 1 which is:6,7-dimethyl-5,7,13-triazatetracyclo[9.3.1.02,10.04,8]pentadeca-2(10),3,5,8-tetraene; or a pharmaceutically acceptable salt thereof.
- 7. A compound according to claim 1 which is:6,7dimethyl-5,8,14-triazatetracyclo[10.3.1.02,11.04,9]hexadeca-2(11),3,5,7,9-pentaene; or a pharmaceutically acceptable salt thereof.
- 8. A compound according to claim 1 which is:5,8,14-triazatetracyclo[10.3.1.02,11.04,9]hexadeca-2(11),3,5,7,9-pentaene; or a pharmaceutically acceptable salt thereof.
- 9. A compound according to claim 1 which is:14-methyl-5,8,14-triazatetracyclo[10.3.1.02,11.04,9]hexadeca-2(11),3,5,7,9-pentaene; or a pharmaceutically acceptable salt thereof.
- 10. A compound according to claim 1 which is:5-oxa-7,13-diazatetracyclo[9.3.1.02,10.04,8]pentadeca-2(10),3,6,8-tetraene; or a pharmaceutically acceptable salt thereof.
- 11. A compound according to claim 1 which is:7-methyl-5-oxa-6,13-diazatetracyclo[9.3.1.02,10.04,8]pentadeca-2,4(8),6,9-tetraene; or a pharmaceutically acceptable salt thereof.
- 12. A pharmaceutical composition comprising an amount of a compound according to claim 1 and a pharmaceutically acceptable carrier.
- 13. A method for reducing nicotine addiction or aiding in the cessation or lessening of tobacco use in a mammal, comprising administering to said mammal an amount of a compound according to claim 1 that is effective in reducing nicotine addiction or aiding in the cessation or lessening of tobacco use.
- 14. A method for treating a disorder or condition selected from inflammatory bowel disease, ulcerative colitis, pyoderma gangrenosum, Crohn's disease, irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amyotrophic lateral sclerosis (ALS), cognitive dysfunction, hypertension, bulimia, anorexia, obesity, cardiac arrythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supranuclear palsy, chemical dependencies and addictions; dependencies on, or addictions to, nicotine, tobacco products, alcohol, benzodiazepines, barbiturates, opioids or cocaine; headache, stroke, traumatic brain injury (TBI), obsessive-compulsive disorder (OCD), psychosis, Huntington's Chorea, tardive dyskinesia, hyperkinesia, dyslexia, schizophrenia, multi-infarct dementia, age related cognitive decline, epilepsy, petit mal absence epilepsy, senile dementia of the Alzheimer's type (AD), Parkinson's disease (PD), attention deficit hyperactivity disorder (ADHD) and Tourette's Syndrome in a mammal, comprising administering to a mammal in need of such treatment an amount of a compound according to claim 1 that is effective in treating such disorder or condition.
- 15. A compound of the formula (I′) whereinR2 and R3, together with the carbons to which they are attached, form a four to seven membered monocyclic, or ten to fourteen membered bicyclic, carbocyclic ring that can be saturated or unsaturated, wherein from one to three of the nonfused carbon atoms of said monocyclic rings, and from one to five of the carbon atoms of said bicyclic rings that are not part of the benzo ring shown in formula I, may optionally and independently be replaced by a nitrogen, oxygen or sulfur, and wherein said monocyclic and bicyclic rings may optionally be substituted with one or more substituents that are selected, independently, from (C1-C6) alkyl optionally substituted with from one to seven fluorine atoms; (C1-C6)alkoxy optionally substituted with from one to seven fluorine atoms; nitro, cyano, halo, (C2-C6)alkenyl, (C2-C6)alkynyl, hydroxy, amino, (C1-C6)alkylamino and ((C1-C6)alkyl)2amino, —CO2R4, —CONR5R6, —SO2NR7R8, —C(═O)R13 and —XC(═O)R13; wherein each R4, R5, R6, R7, R8 and R13 is selected, independently, from hydrogen and (C1-C6) alkyl, or R5 and R6, or R7 and R8 together with the nitrogen to which they are attached, form a pyrrolidine, piperidine, morpholine, azetidine, piperazine, —N—(C1-C6)alkylpiperazine or thiomorpholine ring, or a thiomorpholine ring wherein the ring sulfur is replaced with a sulfoxide or sulfone; and each X is, independently, (C1-C6)alkylene; and P′ is COOR16 wherein R16 is allyl, 2,2,2-trichloroethyl or (C1-C6)alkyl; —C(═O)NR5R6 wherein R5 and R6 are selected, independently, from hydrogen and (C1-C6) alkyl, or R5 and R6 together with the nitrogen to which they are attached, form a pyrrolidine, piperidine, morpholine, azetidine, piperazine, —N—(C1-C6)alkylpiperazine or thiomorpholine ring, or a thiomorpholine ring wherein the ring sulfur is replaced with a sulfoxide or sulfone; —C(═O)H, —C(═O)(C1-C6)alkyl wherein the alkyl moiety may optionally be substituted with from 1 to 3 halo atoms; benzyl, or t-butoxycarbonyl (t-Boc).
Parent Case Info
This application is a national stage entry under 35 U.S.C. §371 of PCT/IB98/01813, filed Nov. 13, 1998 which claims the benefit of U.S. Provisional Application Ser. No. 60/070,245, filed Dec. 31, 1997.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
PCT/IB98/01813 |
|
WO |
00 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO99/35131 |
7/15/1999 |
WO |
A |
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
3471503 |
Carson |
Oct 1969 |
A |
Foreign Referenced Citations (5)
Number |
Date |
Country |
0 955 301 |
Nov 1999 |
EP |
1 078 637 |
Feb 2001 |
EP |
WO 9955680 |
Nov 1999 |
WO |
WO 0044755 |
Aug 2000 |
WO |
WO 0045846 |
Aug 2000 |
WO |
Non-Patent Literature Citations (1)
Entry |
Mazzocchi et al., Synthesis and Pharmacological Activity of 2,3,4,5-Tetrahydro1,5 methano-1H-3-benzazepines, Journal of Medicinal Chemistry, vol. 22, No. 4, pp. 455-457, 1979. |
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/070245 |
Dec 1997 |
US |